Biogen to Cease Drug Manufacturing in Cambridge, MA

Jun 23, 2016

Biogen will stop producing drugs at its Cambridge, Massachusetts plant by year-end, a decision that could lead to up to 285 layoffs.

The company is looking to sublease its bioprocessing operation in Kendall Square, but if another tenant can’t be found, Biogen will shut down the 66,000-square-foot plant.

The plant in Cambridge makes two multiple sclerosis drugs, Avonex and Plegridy, and the hemophilia A treatment Eloctate, in 2,000-liter bioreactors. Production of these drugs will be moved to larger sites in North Carolina and Europe.

Read the Boston Globe article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments